RxDoctor Payments DataLook up a doctor →

Carmen Magistro, PA

Medical · Bellevue, NENPI 1841258563

Payments from drug & device makers

$7,820in general payments, 2019–2025

Across 515 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$914
  • Lilly USA, LLC$864
  • AstraZeneca$748
  • Antares Pharma, Inc.$417
  • Amgen$349
  • plus $3K from 48 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)80$1,181
Novo Nordisk71$914
Lilly USA, LLC71$864
AstraZeneca30$748
Antares Pharma, Inc.51$417
Amgen(2 entities)26$349
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$327
Pfizer17$301
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$246
Johnson & Johnson11$181
Astellas Pharma US Inc8$170
Jazz Pharmaceuticals Inc.10$149
Bayer8$132
Axsome Therapeutics, Inc.7$129
Amarin Pharma, Inc.9$124
Merck8$113
Medtronic3$90
Biohaven Pharmaceutical Holding Company Ltd.5$88
Electromed, Inc.2$81
Otsuka America Pharmaceutical, Inc.3$77
Takeda Pharmaceuticals U.S.A., Inc.5$71
E.r. Squibb & Sons, L.L.C.4$66
Philips North America LLC4$64
Exact Sciences4$58
Acella Pharmaceuticals, LLC3$56
Azurity Pharmaceuticals, Inc.3$52
Arbor Pharmaceuticals, Inc.3$49
Lundbeck LLC3$47
Edwards Lifesciences2$46
Grifols USA, LLC2$45
Gilead2$44
Idorsia Pharmaceuticals US Inc3$44
Seqirus USA Inc2$39
Kowa Pharmaceuticals America, Inc.3$37
Baxter Healthcare1$36
Genentech USA, Inc.2$34
Tolmar, Inc.2$34
Sanofi Pasteur Inc.1$32
Mylan Specialty L.p.2$31
Lexicon Pharmaceuticals, Inc.2$30
Actelion Pharmaceuticals US, Inc.2$27
Biohaven Pharmaceuticals, Inc.1$21
Halozyme Inc1$18
Sanofi-aventis U.S. LLC1$17
Nestle Healthcare Nutrition Inc.1$16
Ironwood Pharmaceuticals, Inc1$16
Ultragenyx Pharmaceutical Inc.1$16
Mayne Pharma Commercial LLC1$15
Clarus Therapeutics Inc.2$15
Abbott1$14
Esperion Therapeutics, Inc.1$14
Eisai Inc.1$13
GSK1$12
Boehringer Ingelheim1$12

How this compares

$7,820 in reported general payments places this provider in the 95th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska →

Medicare billing

Part B allowed, 2024
$137,263
Medicare patients
336
Services billed
44,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical in Bellevue

See the full list for Nebraska →

Where these figures come from

Is this you, or does something look wrong? →